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The combination of breast examination and radiographic
mammography (XRMM) are the established methods for breast
cancer detection. However, XRMM lacks sensitivity and specificity
in women with dense breasts, leading to false positive findings in
80% and false negative findings in 10% to 15% of the cases.
Tc-99m Sestamibi (MIS!) scintimammography (SMM) is a new
breast-imaging technique. This study shows that SMM has a posi
tive predictive value of 83% and negative predictive value of 93%,
which is similar to that reported by others. This supports other
published reports that SMM is a potential excellent complimentary
imaging technique to XRMM in improving the accuracy of breast
cancer detection.
Introduction
Breast carcinoma is an important public health problem in the
United States. One in eight women will be diagnosed with breast
cancer, and one woman in 25 will die of the disease. Early detection
is known to improve survival. Currently, the most effective means
to detect breast cancer is XR mammography. However, XRMM
lacks sensitivity and specificity in women with dense breasts,
leading to a low positive predictive value (11% to 30%) which
results in major costs including unnecessary biopsies, anxiety and
residual scarring)2The false negative rate for XR mammography
has been reported to vary from 10% to 15%, which may lead to
delays in biopsy and diagnosis.3Therefore, major endeavors are
justified to improve both the positive and negative predictive values
of screening and diagnostic techniques.
Tc-99m Sestamibi (MIBI) scintimammography is a noninvasive
imaging technique for screening and diagnosis of breast cancer. The
uptake of MIBI in the breast is independent of the presence of dense
breasts seen on XR mammography. Preliminary data show that this
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imaging technique has high sensitivity 95.8% to 100%, specificity
85% to 86.8%, positive predictive value 82.1%, and most important,
high negative predictive value 97.1 %34 Other investigational breast
imaging techniques, such as magnetic resonance imaging (MRI)
showed a sensitivity of 94% and specificity of 37%, while breast
echography had a sensitivity of 49.2%.56 Positron emission
tomography (PET), another nuclear medicine imaging not currently
available in Hawaii, has been shown to have a sensitivity of 80% for
breast cancer detection.7Tc-99m MIBI scintimammography has
been reported in recent studies to have a remarkable potential in
selecting those patients who would benefit most from breast biopsy
and reduce the number of negative biopsies.3
Methods
Patient population
Eighteen women (mean age of 53.9± 10.8 years) were enrolled in
the study with informed consent. Each patient was examined by an
investigator in the supine and upright positions and had XR
mammography before enrollment into the study. Study inclusion
criteria consisted of either a palpable breast mass and/or an abnor
mal XR mammography for which biopsies were recommended.
Mammography
Mammography was performed in standard craniocaudal and
mediolateral oblique projections using a dedicated mammography
unit. Additional views using cone compression and magnification
were performed as indicated. The mammographic results were
collected at the time of the initial interpretation with full knowledge
of available clinical information and the patients’ previous
mammograms. All images were evaluated by two experienced
radiologists. Any disagreement was resolved by consensus.
Scintimammography
Each patient received 20 mCi (74OMBq) Tc-99m MIBI (Cardiolite,
DuPont Pharma, Billerica, Mass) intravenously in the arm con
tralateral to the breast with the abnormality. Breast scintigraphy was
performed using a single-head gamma camera (ADAC Genesis),
equipped with a high resolution collimator. The spectrometer was
centered at 140 keV with a 10% window. Patients were imaged in
the prone position, which allowed the breast being imaged to be
freely dependent of the imaging table. Each breast was imaged
separately in order to exclude activity in the opposite breast.
Three standard planar images of the breasts and chest were
acquired with a l28x128 matrix for 10 minutes per view. A 10-
minute lateral image of the breast with the suspected lesion began
5 minutes post-injection. The patient was then repositioned with the
contralateral breast dependent, and another lateral image was ac
quired. A final 10-minute anterior chest image was obtained in the
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supine position with the patient’s arms raised for visualization of
both axillae.
The amount of radiation to the patient from one dose of 20 mCi of
Tc-99m MIBI would be 0.13 rad to the breasts (compared with mean
radiation dose of 0.16 rad by standard 2 view XR mammogram, plus
0.08 rad per additional view). The estimated amount of total body
radiation from one dose of Tc-99m MIBI is 0.33 rad, which is
roughly equivalent to that of radiographic imaging of the lumbosac
ral spine.
All images were evaluated for abnormal Tc-99m MIBI uptake by
two nuclear medicine physicians blinded to the patients’ clinical
presentation and mammographic results. Any disagreement was
resolved by consensus.
for XRMM (p>O.75). The specificity of SMM is 93% compared
with 27% for XRMM (p<O.OO5) (Fig I). The positive predictive
value of SMM is 86% compared with 27% for XRMM. The
negative predictive value of SMM is 93% compared with 67% for
XRMM (Fig 2).
Discussion
Approximately 175,000 women in the United States are diag
nosed as having breast cancer each year, representing 32% of all
women diagnosed with cancer. Breast cancer also is causing more
than 150,000 hospitalizations and 44,000 deaths annually in the
U.S. Efforts to reduce morbidity and mortality from breast cancer
have focused on a combination of breast self-examination, clinical
Data analysis
XRMM results were classified into three categories: normal, 0,
benign or very low suspicious, 1, suspicious, 2. Categories 0 to 1 are
classified as negative while category 2 is classified as positive
interpretation for cancer. Similarly, SMM results were classified
into 3 categories by visual scoring: normal, 0, benign, 1, and
suspicious, 2. Categories 0 to 1 are classified as negative while
category 2 is classified as positive interpretation for cancer. Results
of XRMM and SMM were correlated with excisional biopsy in 20
lesions and core-needle biopsy in one lesion. Statistical analysis was
performed based on the comparison of the proportions as paired
samples.8
Results
Eighteen women with 21 lesions were studied (mean age of
53.9±10.8 years): There were 9 palpable masses and 15 abnormal
XR mammographic lesions. Four of the 15 abnormal XR
mammographic lesions were palpable. Pathology results were ob
tained by excisional biopsies in 20 lesions and core-needle biopsy
in one within one month after XR mammogram and
scintimammogram.
There were 6 malignant primary breast cancer lesions and 15
benign lesions. Three of the 6 malignant lesions were palpable. The
size of malignant lesions on pathology ranged from 0.1 cm to 1.8cm
measured in the largest diameter with the mean size of 1.1 ± 0.6 cm.
Scintimammogram correctly detected 5 of 6 malignant lesions,
whereas XR mammogram detected only 4 of 6. Scintimammogram
identified 14 of 15 benign lesions correctly while XR mammogram
identified only 4 of 15. Twelve patients had 15 benign lesions and
only one patient had a false positive SMM result. By contrast, 11 had
false positive results by XRMM (Table 1).
The sensitivity of SMM in this study is 83% compared with 67%
Table 1 —Results of Radiographic Mammography (XRMM) and
Scintimammography (SMM).
TP FP EN TN
XRMM 4 11 2 4
SMM 5 1 1 14
PE = Physical examination; XR = radiographic mammography;
SMM = scintimammography; TP = true positive; PP = false positive;
EN = false negative; TN = true negative.
67%
Fig 1.—Comparison of the sensitivity and specificity of
scintimammography (SMM) and radiographic mammography (XRMM).
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Fig 2.—Comparison of the positive and negative predictive values of
scintimammography (SMM) and radiographic mammography (XRMM).
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breast examination, and mammography. However, 11% to 30% of
women with breast cancer have benign-appearing mammograms.’9
This indicates the importance of physical examination and the need
for the development of an effective alternative imaging technique
for this subset of patients.
Of those women who are referred for breast biopsy, only one in
five is a true positive, and therefore, has a malignant breast tumor.
The incidence of benign breast biopsy is even higher in younger
women, about 16.4 benign to one malignant biopsy in the 35 to 39
age group, and 9.5 to one in the 40 to 44 age group. The high benign
biopsy rates in these younger women probably reflect the high
incidence of fibrocystic disease in women of this age group.’°
Recent studies have shown that in the subset of patients with
radiodense breasts, surgical or radiotherapy scars, or breast prosthe
sis, SMM is an excellent complimentary imaging technique to
XRMM in improving the accuracy of breast cancer detection.”
Tc-99m Sestamibi (MIBI) is an FDA-approved radio-pharma
ceutical that has been used mainly in myocardial perfusion studies
for the detection of coronary artery disease. It also has been used for
other tumor imaging, including brain, bone, thyroid, parathyroid
and lung. It is not metabolized, and it is excreted into the biliary
system within one hour.
The exact mechanism of cellular uptake of Tc-99m MIBI by
carcinomas is unknown but recent data suggest it is concentrated in
the mitochondria. Laboratory studies also have shown that MIBI
uptake may be impeded by the presence of p-glycoprotein, a
membrane transporter on cell surfaces, found in multidrug-resistant
cancers.’2This may lead to false-negative readings on SMM. On the
other hand, SMM may have the potential to determine multidrug
resistant tumor and help in the chemotherapy management of breast
cancer patients.
The one false negative case in our study is a woman who had a
surgical biopsy for a palpable breast mass. The pathology showed
intraductal adenocarcinoma that was missed by XRMM. Her SMM
was done about two weeks after her surgical biopsy showing
minimal uptake which was classified as benign inflammatory
reaction after biopsy. Her mastectomy specimen showed a single
0.1 x 0.1 cm residual tumor focus. Other investigators have reported
low sensitivity of SMM for the detection of breast lesions less than
6 mm.’3A larger scale multi-center trial is underway to validate the
accuracy of SMM.
The SMM of the one false positive case in this study showed a
slight degree of focal uptake. This patient had no palpable mass but
an abnormal XRMM indicating suspicious subareolar
microcalcification. The biopsy result showed fibrocystic disease
with benign ductal adenosis. Others have reported false-positive
SMM results in highly proliferative conditions such as fibroadenoma
and fibrocystic disease.3Semiquantitative evaluation of MIBI up
take using region of interest technique may enhance the specificity
of SMM for detecting breast cancer.’4
SMM is a promising new imaging technique with preliminary
data indicating improved accuracy for the detection of breast
cancer. This new imaging technique has the potential to decrease the
number of benign biopsies, thereby substantially reduce physical
and psychological scarring, costs, and morbidity of unnecessary
biopsies, thereby, benefiting both patients and third-party payers. It
also may make mammographic screening more cost-effective,
especially among women under 50.’
Conclusion
The combination of breast examination and XR mammography
(XRMM) is the established method for breast cancer detection.
XRMM remains the procedure of choice in screening; however, it
has a number of critical limitations leading to false positive findings
in 73% and false negative findings in 33% of our study.
Breast scintigraphy (SMM) is a noninvasive nuclear medicine
imaging procedure with preliminary data indicating high accuracy
for the detection of breast cancer. SMM has the potential to reduce
the large number of breast biopsies performed for benign, non
neoplastic conditions. In our small study sample, SMM appears to
be both more sensitive (83% versus 67%) and specific (93% versus
27%) than XRMM. Further studies are warranted to determine the
role of SMM as a breast cancer detection tool and to define the
subgroups of women who would benefit most from this test.
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